Skip to Main Content

Paper Details

Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
Support Care Cancer
8
2016
5-HT3RA, Emesis, MG, PAL, Patients, TMZ, cRINV, cancer, corticosteroids, emesis, malignant glioma, nausea, palonosetron, patients, primary malignant glioma, temozolomide, vomiting
Author NameAffiliation
John P KirkpatrickDuke University Health System
Henry S FriedmanDuke University Health System
Henry S FriedmanDuke University Medical Center, South Hospital
Henry S FriedmanDuke University Health System
Henry S FriedmanDuke University Health System
Henry S FriedmanDuke University Health System
  • 1 - 6

Datasets

Release 1.2